Adverse events of after-loading high dose rate brachytherapy reported to the United States Food and Drug Administration (FDA)
To provide an assessment of safety regarding high-dose-rate after-loading brachytherapy (HDR-BT) based on adverse events reported to the OpenFDA, an open access database maintained by the United States Food and Drug Administration (FDA).
Source: Brachytherapy - Category: Cancer & Oncology Authors: Destie Provenzano, Kevin Rao, Gizem Cifter, Neil Taunk, Benjamin Fischer-Valuck, Alexander Lin, Mehrdad Sarfaraz, Hamid Aghdam, Martin Ojong-Ntui, Murray H. Loew, Sharad Goyal, Yuan James Rao Source Type: research